You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NK cell lymphoma-nasal type

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 28, 2022

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)

Recruiting
  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Dec 7, 2021

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Shanghai (Methotrexate, Etoposide, Dexamethasone)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
    Ruijin Hospital
Aug 19, 2021

Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +14 more
  • Cholecalciferol
  • Laboratory Biomarker Analysis
  • Scottsdale, Arizona
  • +4 more
Jan 16, 2023

LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive

Recruiting
  • LGLL - Large Granular Lymphocytic Leukemia
  • +13 more
  • Duarte, California
  • +9 more
Aug 9, 2022

Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Not yet recruiting
  • Lymphoma
  • +8 more
  • No interventions need to be specified for this study
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 15, 2023

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Trial in Shanghai (tislelizumab, azacytidine, lenalidomide, tislelizumab,

Recruiting
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • tislelizumab, azacytidine, lenalidomide
  • tislelizumab, etoposide, pegaspargase
  • Shanghai, Shanghai, China
    Xinhua Hospital,Shanghai Jiao Tong University School of Medicine
Sep 17, 2021

Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)

Recruiting
  • Lymphoma
  • Radiation Therapy
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 9, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022

Lymphoma Trial in Philadelphia (Pembrolizumab)

Withdrawn
  • Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
May 5, 2021

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Guangzhou (pegaspargase, Gemcitabine, Oxaliplatin)

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021

Effect of Drugs Trial in Nanjing (Sintilimab)

Completed
Has Results
  • Effect of Drugs
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Hospital
Dec 20, 2020

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Guangzhou (Pegaspargase, Anti-PD-1 mAb, Definitive intensity-modulated

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Dec 16, 2020

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023